RecruitingPhase 3NCT03969329

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Studying Complication in hemodialysis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Amgen
Principal Investigator
MD
Amgen
Intervention
Etelcalcetide(drug)
Enrollment
24 target
Eligibility
2-17 years · All sexes
Timeline
20192027

Study locations (23)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03969329 on ClinicalTrials.gov

Other trials for Complication in hemodialysis

Additional recruiting or active studies for the same condition.

See all trials for Complication in hemodialysis

← Back to all trials